The purpose of this study is to assess the safety of transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with hepatocellular carcinoma
The purpose of this study is to assess the peri-operative morbidity and mortality of supraselective ablative transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with HCC
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Patients will receive Sirsphere trans-arterial radioembolization before surgery
Institut Jules Bordet
Brussels, Belgium
Erasme Hosptial
Brussels, Belgium
Peri-operative morbidity
peri-operative morbidity of supraselective ablative transarterial radioembolization prior to surgical resection or radiofrequency in cirrhotic patients with HCC (starting from date of inclusion till 90 days after surgery or hospital discharge if more than 90 days)
Time frame: 3 months after surgery
Survival
Assessment of the overall disease free survival and Overall Survival
Time frame: 3 years
One and three years survival
Estimation of disease free survival and overall survival rates after 1 and 3 years
Time frame: one and three years
Tumor regression
Assessment of tumour size regression after Trans-arterial radioembolization by MRI
Time frame: 8 weeks after Trans-arterial radioembolization
Functional Imaging
Assessment of imaging parameters changes (DW-MRI, FDG-PET/CT) and MAA-SPECT-CT in relation to the outcome measured by tumour regression after TARE, disease free and overall survival.
Time frame: 3 years
Contra-lateral Lobe Hypertrophy
Assessment of TARE induced liver contralateral lobe hypertrophy (volumetric measurement by MRI).
Time frame: 3 Years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.